

# Fernando Arribas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3628514/publications.pdf>

Version: 2024-02-01

147  
papers

10,383  
citations

172457

29  
h-index

36028

97  
g-index

167  
all docs

167  
docs citations

167  
times ranked

8991  
citing authors

#	ARTICLE	IF	CITATIONS
1	The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. <i>BMC Medicine</i> , 2022, 20, 14.	5.5	7
2	Response by Caravaca Pérez et al to Letter Regarding Article, "Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure". <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009258.	3.9	0
3	Remote heart failure management using the HeartLogic algorithm. RE-HEART registry. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2022, 75, 709-716.	0.6	4
4	Primary vs. Secondary Heart Failure Diagnosis: Differences in Clinical Outcomes, Healthcare Resource Utilization and Cost. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 818525.	2.4	6
5	Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 691-700.	1.7	6
6	Impact of late-onset cytomegalovirus infection in the development of cardiac allograft vasculopathy in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13479.	1.7	1
7	Diagnosis, prevention, and management of delirium in the intensive cardiac care unit. <i>American Heart Journal</i> , 2021, 232, 164-176.	2.7	31
8	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
9	The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2021, 57, 2100115.	6.7	5
10	Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations. <i>Kardiologia Polska</i> , 2021, 79, 386-392.	0.6	4
11	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy. <i>Current Cardiology Reviews</i> , 2021, 17, 294-305.	1.5	3
12	Efectos cardiovasculares de la mexiletina para el tratamiento de la miotonía en la distrofia miotónica tipo 1. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 986-986.	1.2	0
13	Comentarios a la guía ESC/EACTS 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 378-383.	1.2	2
14	Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 583-593.	1.4	15
15	Miocardiópatía dilatada y distrofia muscular de cinturas leve causada por la variante genética p.Gly424Ser en fukutina. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 987-987.	1.2	0
16	Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008166.	3.9	13
17	Selective Segmental Pulmonary Angiography: Anatomical, Technical and Safety Aspects of a Must-Learn Technique in Times of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 3358.	2.4	2
18	Sex Differences in Chronic Thromboembolic Pulmonary Hypertension. Treatment Options over Time in a National Referral Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 4251.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Impact of Coronavirus Disease 2019 on Cardiac Arrhythmia Care: Experience of a Spanish Tertiary Hospital During the Health Crisis Triggered by the First Wave of the Pandemic. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2021, 12, 4688-4698.	0.5	1
20	El papel de la genética en la hipertensión arterial pulmonar asociada con cardiopatías congénitas. <i>Revista Española De Cardiología</i> , 2021, 74, 884-886.	1.2	2
21	Percutaneous left atrial appendage closure in the presence of thrombus: a single-center experience. <i>Revista Española De Cardiología (English Ed )</i> , 2021, 74, 886-888.	0.6	0
22	Electrocardiogram Changes in the Spectrum of TTNtv Dilated Cardiomyopathy: Accuracy and Predictive Value of a New Index for LV-Changes Identification. <i>Heart Lung and Circulation</i> , 2021, 30, 1487-1495.	0.4	0
23	Complications associated with peripherally inserted central catheters and Hickman, in patients with advanced pulmonary hypertension treated with intravenous prostanoids. <i>Respiratory Medicine</i> , 2021, 189, 106649.	2.9	0
24	A new mutation affecting the converter region of the beta-myosin heavy chain related to hypertrophic cardiomyopathy with poor prognosis. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 73, 180-183.	0.6	0
25	Control clásico en la EPOC: ¿un nuevo objetivo terapéutico?. <i>Archivos De Bronconeumología</i> , 2020, 56, 68-69.	0.8	20
26	2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 655-720.	2.2	647
27	A novel complex structural genetic variant in DSP causing a form of arrhythmogenic cardiomyopathy. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 73, 269-271.	0.6	0
28	Ivabradine for chronic heart rate control in persistent atrial fibrillation. Design of the BRAKE-AF project. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 73, 368-375.	0.6	10
29	Differences between cardiologists' perceptions and clinical reality of the quality of anticoagulation with vitamin K antagonists in Spain. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 73, 332-334.	0.6	0
30	Heart transplantation during the COVID-19 pandemic: follow-up organization and characteristics of infected patients. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 73, 1077-1080.	0.6	6
31	Do we have a new drug for heart rate control in patients with permanent atrial fibrillation? Response. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 73, 1083-1084.	0.6	0
32	Comentarios a la guía ESC 2019 sobre síndromes coronarios crónicos. <i>Revista Española De Cardiología</i> , 2020, 73, 439-444.	1.2	7
33	Miocardio patológica dilatada asociada a variantes tipo truncamiento en titina: no solo recuperación de la FEVI, también mantenimiento. <i>Revista Española De Cardiología</i> , 2020, 73, 589-592.	1.2	0
34	The p.P888L SAP97 polymorphism increases the transient outward current (I <sub>to,f</sub> ) and abbreviates the action potential duration and the QT interval. <i>Scientific Reports</i> , 2020, 10, 10707.	3.3	7
35	Primera experiencia en España de la modulación de la contractilidad cardíaca. Una nueva alternativa para los pacientes con insuficiencia cardíaca. <i>Revista Española De Cardiología</i> , 2020, 73, 855-857.	1.2	1
36	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. <i>Diagnostics</i> , 2020, 10, 548.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Feasibility of a Noninvasive Operability Assessment in Chronic Thromboembolic Pulmonary Hypertension under Real-World Practice. <i>Diagnostics</i> , 2020, 10, 855.	2.6	5
38	Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 348-353.	0.6	2
39	Clinical course of COVID-19 in pulmonary arterial hypertension patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 775-778.	0.6	15
40	Heart Transplantation in a Distant Island Population: Accessibility and Outcomes in Patients From the Canary Islands Transplanted in Madrid. <i>Transplantation</i> , 2020, 104, 223-226.	1.0	1
41	Influence of long-standing pulmonary arterial hypertension and its severity on pulmonary artery aneurysm development. <i>Heart and Vessels</i> , 2020, 35, 1290-1298.	1.2	1
42	Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry. <i>Europace</i> , 2020, 22, 888-896.	1.7	13
43	Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2509.	4.1	7
44	Ivabradina para el control cr3nico de la frecuencia cardiaca en fibrilaci3n auricular permanente. Dise±o del proyecto BRAKE-AF. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 368-375.	1.2	11
45	Diferencias entre la percepci3n de los cardi3logos y la realidad sobre la calidad de la anticoagulaci3n con antagonistas de la vitamina K en Espa±a. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 332-334.	1.2	4
46	Levosimend3n como terapia puente a trasplante cardiaco en pacientes con insuficiencia cardiaca avanzada. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 422-424.	1.2	9
47	Comentarios a la gu±a ESC/EAS 2019 sobre el tratamiento de las dislipemias. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 348-353.	1.2	0
48	Comments on the 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 354-360.	0.6	0
49	Comentarios a la gu±a ESC 2019 sobre taquicardia supraventricular. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 445-451.	1.2	0
50	Are there real differences between the treatment for young and elderly patients with chronic thromboembolic pulmonary hypertension?. <i>European Heart Journal</i> , 2020, 41, .	2.2	1
51	Could we suspect pulmonary veno-occlusive disease with a cardiopulmonary exercise test?. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
52	Pulmonary hypertension and pregnancy. Is it time to reconsider recommendations in certain groups? Contemporary outcomes in a tertiary referral centre. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
53	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 224-232.	0.6	14
54	Comments on the 2018 ESC/EACTS Guidelines for Myocardial Revascularization. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 16-20.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Multiple ICD shocks in a patient with dilated cardiomyopathy: What is the mechanism?. Journal of Cardiovascular Electrophysiology, 2019, 30, 781-784.	1.7	1
56	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Hypertension, 2019, 74, 130-136.	2.7	12
57	Electroanatomical delimitation of recipient atrium in heart transplantation. Europace, 2019, 21, 346-346.	1.7	0
58	Comments on the 2018 ESC Guidelines for the Management of Cardiovascular Diseases During Pregnancy. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 109-114.	0.6	2
59	Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2019, 123, 474-481.	1.6	14
60	Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Nephrology Dialysis Transplantation, 2019, 34, 1864-1875.	0.7	40
61	Diagnostic yield of the implantable loop recorder in octogenarians. European Geriatric Medicine, 2019, 10, 129-133.	2.8	4
62	Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design. Clinical Research in Cardiology, 2018, 107, 539-547.	3.3	12
63	Super-response to cardiac resynchronization therapy may predict late phrenic nerve stimulation. Europace, 2018, 20, 1498-1505.	1.7	2
64	Pacemapping guided by defibrillator electrograms for ventricular tachycardia ablation in a patient with ARVD/C. Journal of Cardiovascular Electrophysiology, 2018, 29, 336-336.	1.7	0
65	Comments on the 2018 ESC Guidelines for the Diagnosis and Management of Syncope. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 787-793.	0.6	0
66	Entrapment of "ePVâ€Tracker" guidewire in the pulmonary veins during atrial fibrillation ablation with PVAC Gold. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1572-1574.	1.2	2
67	Impact of Late Onset CMV Replication After Heart Transplant. Journal of Heart and Lung Transplantation, 2018, 37, S354.	0.6	0
68	Mechanistic insights of the left ventricle structure and fibrosis in the arrhythmogenic mitral valve prolapse. Global Cardiology Science & Practice, 2018, 2018, 4.	0.4	5
69	Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. European Heart Journal, 2017, 38, ehw230.	2.2	87
70	Comentarios a la guÃa ESC 2016 sobre el diagnÃstico y tratamiento de la fibrilaciÃn auricular. Revista Espanola De Cardiologia, 2017, 70, 2-8.	1.2	11
71	Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. Revista Espanola De Cardiologia (English Ed ), 2017, 70, 72-77.	0.6	5
72	LATE OCCURRENCE OF PHRENIC NERVE STIMULATION: A POTENTIAL PITFALL AMONG SUPER RESPONDERS?. Journal of the American College of Cardiology, 2017, 69, 355.	2.8	0

#	ARTICLE	IF	CITATIONS
73	Change in the Grade of Preexcitation and Progressive Prolongation of Sâ€Delta Interval. Journal of Cardiovascular Electrophysiology, 2016, 27, 1356-1359.	1.7	0
74	Atrial Rate-Responsive Pacing and Incidence of Sustained Atrial Arrhythmias in Patients with Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 548-556.	1.2	9
75	Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 1119-1125.	0.6	10
76	Comments on the 2016 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 894-899.	0.6	3
77	EstimulaciÃ³n frÃ©nica de apariciÃ³n tardÃa en un paciente superrespondedor a la terapia de resincronizaciÃ³n. Â¿El precio del Ã©xito?. Revista Espanola De Cardiologia, 2016, 69, 868-870.	1.2	2
78	Late Phrenic Nerve Stimulation in a Super-responder to Cardiac Resynchronization Therapy. The Toll of Success?. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 868-870.	0.6	0
79	The Usefulness of Vernakalant in Maintaining Sinus Rhythm During Ablation Procedures. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 708-709.	0.6	0
80	Left Free Wall Accessory Pathway Ablation in the Presence of a Mechanical Mitral Prosthesis. Journal of Cardiovascular Electrophysiology, 2016, 27, 759-760.	1.7	2
81	Comments on the 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 94-101.	0.6	4
82	Phrenic paralysis during cardiac electronic device implantation: incidence, causes and clinical course. Europace, 2016, 18, 1561-1564.	1.7	3
83	A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redinâ€SCORE. European Journal of Heart Failure, 2015, 17, 818-827.	7.1	50
84	When is an Outflow Tract PCV Completely Ablated?. Journal of Cardiovascular Electrophysiology, 2015, 26, 814-815.	1.7	1
85	A particular malignant case of untreatable ventricular arrhythmias in arrhythmogenic cardiomyopathy. International Journal of Cardiology, 2015, 182, 307-308.	1.7	0
86	Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiology, 2014, 10, 381-393.	1.2	21
87	Statistics on the use of cardiac electronic devices and electrophysiological procedures in 55 ESC countries: 2013 report from the European Heart Rhythm Association (EHRA). Europace, 2014, 16, i1-i78.	1.7	46
88	Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). European Heart Journal, 2014, 35, 501-507.	2.2	285
89	Cavo-tricuspid isthmus radiofrequency ablation using a novel remote navigation catheter system in patients with typical atrial flutter. Europace, 2014, 16, 558-562.	1.7	17
90	Comparison of Radiofrequency Catheter Ablation of Drivers and Circumferential Pulmonary Vein Isolation in Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 64, 2455-2467.	2.8	197

#	ARTICLE	IF	CITATIONS
91	Resistant Hypertension and Renal Denervation. Considerations on the Results of the Symplicity HTN-3 Trial. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 881-882.	0.6	1
92	An unusual mechanism of asystole. Journal of Electrocardiology, 2014, 47, 951-952.	0.9	0
93	What is the origin of the arrhythmia?. Journal of Electrocardiology, 2014, 47, 383.	0.9	0
94	Comments on the 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 6-14.	0.6	5
95	Clinical Profile and Incidence of Ventricular Arrhythmia in Patients Undergoing Defibrillator Generator Replacement in Spain. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 986-992.	0.6	5
96	Comment on the Management of Resistant Hypertension in a Multidisciplinary Unit of Renal Denervation: Protocol and Results. Response. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 830-831.	0.6	0
97	Management of Resistant Hypertension in a Multidisciplinary Unit of Renal Denervation: Protocol and Results. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 364-370.	0.6	1
98	Comentarios a la guÃa de prÃctica clÃnica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevaciÃn del segmento ST. Revista Espanola De Cardiologia, 2013, 66, 5-11.	1.2	42
99	Manejo de la hipertensiÃn resistente en una unidad multidisciplinaria de denervaciÃn renal: protocolo y resultados. Revista Espanola De Cardiologia, 2013, 66, 364-370.	1.2	19
100	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 877-884.	7.1	27
101	An electrocardiographic proof of substrate modification during ablation of tetralogy of Fallot associated right ventricular tachycardia. Europace, 2012, 14, 1474-1474.	1.7	2
102	The EHRA White Book. Europace, 2012, 14, ii1-ii55.	1.7	25
103	Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry. Journal of Hypertension, 2012, 30, 713-719.	0.5	97
104	Proarrhythmic Potential of Amiodarone: An Underestimated Risk?. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 292-294.	0.6	3
105	PCV91 The Impact of Atrial Fibrillation Symptoms in the Health Related Quality of Life in Spanish Population (Ulises Study). Value in Health, 2012, 15, A378.	0.3	0
106	Single and Inappropriate Shock Delivered Out of Tachycardia: Device Dysfunction?. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 884-886.	1.2	0
107	Clinical implications of supraventricular arrhythmias in patients with severe pulmonary arterial hypertension. International Journal of Cardiology, 2011, 146, 105-106.	1.7	60
108	Implante de desfibrilador como preventiÃn primaria de muerte sÃbita en pacientes en lista de espera de trasplante cardiaco: experiencia de un centro. Revista Espanola De Cardiologia, 2011, 64, 240-242.	1.2	8



#	ARTICLE	IF	CITATIONS
109	Ventricular Fibrillation During AV Reentrant Tachycardia. Journal of Cardiovascular Electrophysiology, 2011, 22, 99-99.	1.7	0
110	Incidence, Determinants, and Prognostic Implications of True Pleomorphism of Ventricular Tachycardia in Patients With Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 33-42.	4.8	16
111	Variation in Quality of Life With Type of Atrial Fibrillation. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Overlo	0.6	10
112	Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace, 2010, 12, 364-370.	1.7	75
113	Core curriculum for the heart rhythm specialist: executive summary. Europace, 2009, 11, 1381-1386.	1.7	23
114	Dual-chamber implantable cardioverter defibrillators reduce clinical adverse events related to atrial fibrillation when compared with single-chamber defibrillators: a subanalysis of the DATAS trial. Europace, 2009, 11, 587-593.	1.7	23
115	Core curriculum for the heart rhythm specialistâ€. Europace, 2009, 11, iii1-iii26.	1.7	45
116	Five Years of Catheter Ablation Procedures in Southâ€Western Europe: Metaâ€Analysis of National Registries. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 506-515.	1.2	12
117	PCV146 HAS THE TYPE OF ATRIAL FIBRILLATION DIFFERENT IMPACT ON HRQOL?. Value in Health, 2009, 12, A340-A341.	0.3	0
118	CV2 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A TRIAL FIBRILLATION:AF-QOL. Value in Health, 2008, 11, A342.	0.3	0
119	47: Clinical Impact and Prognosis of Supraventricular Tachycardias in Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, S76-S77.	0.6	0
120	Data analysis and interpretation of results in DATAS trial: reply. Europace, 2008, 10, 1243-1244.	1.7	0
121	Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	0
122	Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2007, 298, 405-12.	7.4	705
123	Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with atrial fibrillation (AF-QoL). Health and Quality of Life Outcomes, 2007, 5, 37.	2.4	64
124	PCV90 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION:â€œAF-QOLâ€. Value in Health, 2006, 9, A365.	0.3	0
125	Spanish Implantable Cardioverter-Defibrillator Registry. First Official Report of the Spanish Society of Cardiology Working Group on Implantable Cardioverter-Defibrillators (2002â€2004). Revista Espanola De Cardiologia (English Ed ), 2005, 58, 1435-1449.	0.6	0
126	The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator. Europace, 2004, 6, 142-150.	1.7	14



#	ARTICLE	IF	CITATIONS
127	Documento de consenso sobre el tratamiento de la fibrilación auricular en los servicios de urgencias hospitalarios. Revista Espanola De Cardiologia, 2003, 56, 801-816.	1.2	4
128	Bundle-Branch Reentry and the Postpacing Interval After Entrainment by Right Ventricular Apex Stimulation. Circulation, 2001, 103, 1102-1108.	1.6	80
129	Ventricular fibrillation induced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace, 2000, 2, 327-332.	1.7	13
130	Mechanisms of Induction of Typical and Reversed Atrial Flutter. Journal of Cardiovascular Electrophysiology, 1998, 9, 281-291.	1.7	13
131	The Upper Link of Human Common Atrial Flutter Circuit Definition by Multiple Endocardial Recordings during Entrainment. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2924-2929.	1.2	22
132	Atrial Flutter Mapping and Ablation I.. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 841-853.	1.2	97
133	Atrial Flutter Mapping and Ablation II. Radiofrequency Ablation of Atrial Flutter Circuits. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 965-975.	1.2	42
134	Radiofrequency Ablation of Atrial Flutter. Journal of Cardiovascular Electrophysiology, 1996, 7, 60-70.	1.7	67
135	Radiofrequency ablation of atrial flutter. Developments in Cardiovascular Medicine, 1996, , 249-258.	0.1	1
136	Wolff-Parkinson-White Syndrome Presenting as the Permanent Form of Junctional Reciprocating Tachycardia. Journal of Cardiovascular Electrophysiology, 1995, 6, 132-136.	1.7	9
137	Atrial Flutter Ablation: Electrophysiological Landmarks. Journal of Interventional Cardiology, 1995, 8, 677-686.	1.2	2
138	Mechanisms of entrainment of human common flutter studied with multiple endocardial recordings.. Circulation, 1994, 89, 2117-2125.	1.6	80
139	Catheter Ablation of Atrial Flutter Circuits. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 637-642.	1.2	43
140	Radiofrequency ablation of the inferior vena cava-tricuspid valve isthmus in common atrial flutter. American Journal of Cardiology, 1993, 71, 705-709.	1.6	546
141	Radiofrequency catheter ablation for the treatment of human type 1 atrial flutter.. Circulation, 1993, 88, 804-805.	1.6	44
142	Electrophysiologic studies in atrial flutter. Clinical Cardiology, 1992, 15, 667-673.	1.8	57
143	Atrial endocardial mapping in the rare form of atrial flutter. American Journal of Cardiology, 1990, 66, 715-720.	1.6	98
144	Validation of double-spike electrograms as markers of conduction delay or block in atrial flutter. American Journal of Cardiology, 1988, 61, 775-780.	1.6	161

#	ARTICLE	IF	CITATIONS
145	Junctional echoes with slow retrograde conduction without His bundle depolarization: further evidence of reentry within the atrioventricular node. <i>International Journal of Cardiology</i> , 1987, 16, 201-204.	1.7	0
146	Fragmented electrograms and continuous electrical activity in atrial flutter. <i>American Journal of Cardiology</i> , 1986, 57, 1309-1314.	1.6	124
147	Effects of intravenous ajmaline on atrial excitability and conduction in man. <i>European Heart Journal</i> , 1986, 7, 158-164.	2.2	9